Dendreon to offer end-to-end cell therapy manufacturing

By The Science Advisory Board staff writers

June 16, 2021 -- California-based Dendreon Pharmaceuticals announced that it will offer end-to-end manufacturing for complex cell therapies.

The company is one of only four firms that manufacture cell therapies for commercial use in the U.S. In early 2021, Dendreon started to dedicate capacity for later-stage partner programs within its current infrastructure.

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter